APA (7th ed.) Citation

J, F., C, C., P, I., N, P., A, C., S, C., . . . R, A. (2022). High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC. Journal for immunotherapy of cancer, 10(4), . https://doi.org/10.1136/jitc-2021-004197

Chicago Style (17th ed.) Citation

J, Frigola, et al. "High Levels of Chromosomal Aberrations Negatively Associate with Benefit to Checkpoint Inhibition in NSCLC." Journal for Immunotherapy of Cancer 10, no. 4 (2022). https://doi.org/10.1136/jitc-2021-004197.

MLA (9th ed.) Citation

J, Frigola, et al. "High Levels of Chromosomal Aberrations Negatively Associate with Benefit to Checkpoint Inhibition in NSCLC." Journal for Immunotherapy of Cancer, vol. 10, no. 4, 2022, https://doi.org/10.1136/jitc-2021-004197.